Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2125061 | 0.86 | MAPT (0.41) | MAPTTP53 | |
| SCHEMBL2124557 | 0.84 | ROCK2 (0.44) | KMT2AMEN1MAPT | |
| SCHEMBL2123772 | 0.82 | KDM5A (0.41) | MAPTKDM5ATP53 | |
| SCHEMBL2126971 | 0.82 | MAPT (0.41) | MAPTTP53 | |
| SCHEMBL2123116 | 0.81 | KDM5A (0.47) | MAPTKDM5ATP53 | |
| SCHEMBL2123090 | 0.81 | ALDH1A1 (0.45) | KMT2AMEN1MAPTKDM5A | |
| SCHEMBL2872219 | 0.74 | MAPT (0.49) | MAPTKDM5ATP53 | |
| SCHEMBL2126838 | 0.72 | MAPT (0.47) | MAPTKDM5ATP53 | |
| SCHEMBL2123865 | 0.71 | KDM5A (0.50) | MAPTKDM5ATP53 | |
| SCHEMBL2124784 | 0.71 | MAPT (0.46) | KMT2AMEN1MAPTKDM5ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | claimed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | claimed |
| EP-2443123-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | Rigel Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | claimed |
| WO-2010147898-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | claimed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | claimed |
| EP-2827890-B1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | UNIV QUEENSLAND (AU) | 2019-08-28 | — | — | EP | disclosed |
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-08-06 | — | — | US | disclosed |
| EP-2827890-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | The University of Queensland (AU) | 2015-01-28 | — | — | EP | disclosed |
| WO-2013138871-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-09-26 | — | — | WO | disclosed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2443123-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | Rigel Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010147898-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | HLA-DRB1, CD74, CHI3L1 | MAP3K11 4122/4885KMT2A 3682/4885MEN1 3585/4885 |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | MAP3K11 189/4885KMT2A 1554/4885MEN1 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.